Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas: Cases illustrating the importance of serial biopsy during vismodegib usage

JAMA Dermatology

Volumn 150, Issue 9, 2014, Pages 970-973

  Zhu, Gefei A ^a   Sundram, Uma ^a   Chang, Anne Lynn S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN AE1; CYTOKERATIN AE3; PROTEIN P63; VISMODEGIB; ANILIDE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CELL PROLIFERATION; CHEMOSURGERY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NOSE CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPULE; PHOTODYNAMIC THERAPY; SCALP TUMOR; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; BIOPSY; CANCER STAGING; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; NEOPLASMS, MULTIPLE PRIMARY; PATHOLOGY; SKIN NEOPLASMS;

ADULT; ANILIDES; BIOPSY; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PYRIDINES; SKIN NEOPLASMS;

EID: 84908242161     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.583     Document Type: Article

References (12)

1. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J AmAcad Dermatol. 2014;70(1):60-69.
2. Epstein EH. Basal cell carcinomas: attack of the Hedgehog. Nat Rev Cancer. 2008;8(10):743-754.
3. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502-2511.
4. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
5. Kang HC,Wakabayashi Y, Jen KY, et al. Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14Ptch(FVB) mice. J Invest Dermatol. 2013;133(5):1311-1320.
6. Wakabayashi Y, Mao J-H, Brown K, Girardi M, Balmain A. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature. 2007;445(7129):761-765.
7. Iarrobino A, Messina JL, Kudchadkar R, Sondak VK. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinomawith vismodegib. J AmAcad Dermatol. 2013;69(1):e33-e34.
8. Aasi S, Silkiss R, Tang JY, et al. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol. 2013;149(2):242-243.
9. Orouji A, Goerdt S, Utikal J, Leverkus M. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma [published online January 21, 2014]. Br J Dermatol. doi:10.1111/bjd.12840.
10. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324-1325.
11. MaloneyML. What is basosquamous carcinoma? Dermatol Surg. 2000;26(5):505-506.
12. Costantino D, Lowe L, Brown DL. Basosquamous carcinoma: an underrecognized, high-risk cutaneous neoplasm: case study and review of the literature. J Plast Reconstr Aesthet Surg. 2006;59(4):424-428.